New molecular entity
Development and Regulatory status
Phase III Clinical Trials
Selective inhibitor of the endothelin A receptor
IgAN is characterized by the deposition of IgA-containing immune complexes in glomeruli of the kidney, causin inflammatory response that leads to proteinuria and hematuria. IgAN is the most common primary glomerular disease globally and a leading cause of chronic kidney disease (CKD) .